<DOC>
	<DOCNO>NCT00359164</DOCNO>
	<brief_summary>To determine Visudyne photodynamic therapy ( low low fluence rate ) combine intravitreal injection bevacizumab ( Avastin ) compare bevacizumab alone , similar safety efficacy , delay time retreatment bevacizumab initial treatment , subject new wet AMD Hypothesis : PDT combination Avastin either low low fluence rate delay time retreatment reduce average number treatment require , compare Avastin alone , similar safety efficacy profile .</brief_summary>
	<brief_title>Phase II Pilot Study VisudyneÂ® Photodynamic Therapy ( PDT ) ( Low Very Low Fluence ) Combined With Bevacizumab .</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<criteria>new wet AMD</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>AMD</keyword>
	<keyword>Avastin</keyword>
	<keyword>Visudyne</keyword>
	<keyword>Medical condition study AMD</keyword>
</DOC>